effects of stopping glp 1 Two Years After GLP-1s, Most Patients Sustain at Least Some Weight Loss 💊 𝗧𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗮𝗯𝗼𝘂𝘁 𝘀𝘁𝗼𝗽𝗽𝗶𝗻𝗴 𝘆𝗼𝘂𝗿

Of note, over the last years, an array of unimolecular GLP1-based poly-agonists, with different mechanisms of action, have been developed and experimentally validated for the treatment of metabolic syndrome, holding superior efficacy relative to conventional GLP1-RA 33,34,35

As more research emerges and more data becomes available, guidelines will continue to evolve

An increase in the Akkermansia spp

Plasma adiponectin: A contributing factor for cardiac changes in visceral obesity-associated hypertension

Potential references were identified through an extensive search of PubMed for articles published between January 1, 2000, and January 1, 2025